커뮤니티

학술자료

Academic Material

로그인

[Gut Microbiome] The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation

e 2032

모바일 App 사용자에게는 실시간 전송!

The New Eraof Treatment for Obesity and Metabolic Disorders: Evidence and Expectations forGut Microbiome Transplantation

Thilini N.Jayasinghe, Valentina Chiavaroli, David J. Holland, Wayne S. Cutfield andJustin M. O’Sullivan

Liggins Institute,The University of Auckland, Auckland, New Zealand, Department of InfectiousDiseases, Counties Manukau Health, Auckland,

New Zealand, Gravida: NationalCentre for Growth and Development, Auckland, New Zealand

Key Points

• The microbiome has been implicated in the development of obesity.

• Conventional therapeutic methods have limited effectiveness for the treatment of obesity and prevention of related complications.

• Gut microbiome transplantation may represent an alternative and effective therapy for the treatment of obesity.

Obesity has reached epidemic proportions. Despite a better understanding of the underlying pathophysiology and growing treatment options, a significant proportion of obese patients do not respond to treatment. Recently, microbes residing in the human gastrointestinal tract have been found to act as an “endocrine” organ, whose composition and functionality may contribute to the development of obesity. Therefore, fecal/gut microbiome transplantation (GMT), which involves the transfer of feces from a healthy donor to a recipient, is increasingly drawing attention as a potential treatment for obesity. Currently the evidence for GMT effectiveness in the treatment of obesity is preliminary. Here, we summarize benefits, procedures, and issues associated with GMT, with a special focus on obesity.

제목

비만 및 대사장애 치료의 새로운 시대: 장내 미생물총 이식에 대한 증거와 기대

내용

주요 포인트

• 미생물군(마이크로바이옴)은 비만의 발달에 연루되어 있다.

• 통상적인치료 방법은 비만 치료 및 관련 합병증의 예방에 대한 효과가 제한적이다.

• 장내미생물총 이식은 비만 치료를 위한 대안법과 효과적인 치료를 나타낼 수 있다.

비만은 급속한 확산 단계(epidemic proportions)에 이르렀다. 근본적인 병리생리학 및 증가하는 치료법 선택안에 대한

이해가 발전함에도 불구하고, 비만 환자의 상당 부분은 치료에 반응하지 않는다. 최근에 인간의위장관에 거주하는

미생물이 내분비 기관으로 작용하여, 그 구성 및 기능이 비만의 발달에 기여할 수 있는것으로 밝혀졌다.

따라서, 건강한 기증자로부터 대변을 받아 수혜자에게 전달하는 분변 이식(FMT; Fecal Microbiome Transplantation)

혹은 장내 미생물총 이식 (GMT; Gut Microbiome Transplantation)은 비만의 잠재적 치료법으로써 점차 주목받고 있다.

현재 GMT의 비만 치료 효과의 증거는 예비 단계이다. 본 리뷰에서는 비만에 특별히 중점을 두고 GMT 연관 혜택,

절차 및 문제점에 대해 요약한다.

Table 2. Mice studies on gut microbiometransplantation.

장내 미생물총 이식에 대한 쥐 연구 (Frontiers of Cellular and Infection Microbiology, 2016)

Figure 1. Environmental and genetic interactionsbetween the host and the host’s microbiome

impact the development and incidenceof obesity and related disorders.

숙주와 숙주의 미생물 간의 환경적 및 유전적 상호 작용은 비만 및 비만 관련 질환의 발달 및 발병에 영향을 미친다.

(Frontiers of Cellular and Infection Microbiology, 2016)

Keywords

: #GutMicrobiomeTransplantation #GMT #FecalMicrobiomeTransplantation#FMT #Microbiome #Microbiota #GutMicrobiota #GutMicrobiome #Obesity #MetabolicDisorders #Treatment

#장내미생물총이식 #분변이식 #마이크로바이옴 #미생물군 #미생물총 #장내미생물총#장내미생물군 #비만 #대사질환#치료

[출처: Jayasinghe,T. N., Chiavaroli, V., Holland, D. J., Cutfield, W. S., & O'Sullivan, J. M.(2016). The new era of treatment for obesity and metabolic disorders: evidenceand expectations for gut microbiome transplantation. Frontiers in cellular andinfection microbiology, 6, 15.]

㈜마이크로바이옴

http://microbiomekorea.co.kr/

㈜마이크로바이옴은 생명공학 최고의 기술력을 바탕으로 마이크로바이옴 산업의 성장과 발전의 선도적 역할을 하고 있는 대한민국 대표 마이크로바이옴 R&D 전문 기업입니다.

㈜마이크로바이옴은 생명공학 국가연구기관인 한국생명공학연구원과 마이크로바이옴 관련

상품에 대하여 공동연구개발 및 기술이전을 통하여 공동특허 출원과 마이크로바이옴 상품화에 성공하였고, 마이크로바이옴 글로벌 기업이 되기 위하여 연구개발을 지속하고 있습니다.

F T

목록으로

오늘 0 / 전체 60

no.		제목	조회수

20	[Gut Microbiome] The microbiome and innate immunity	2082
19	[Gut Microbiome] Acetate mediates a microbiome–brain–β cell axis to promote metabolic syndrome	2202
18	[Gut Microbiome] The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation	2032
17	[Gut Microbiome] The Gut Microbiome in Human Neurological Disease: A Review	2536
16	[Gut Microbiome] Rapidly expanding knowledge on the role of the gut microbiome in health and disease	2180
15	[Lactobacillus Plantarum] Lactobacillus plantarum inhibits epithelial barrier dysfunction and interleukin-8 secretion induced by tumor necrosis factor-α	2222
14	[Lactobacillus paracasei] Decreased Fat Storage by Lactobacillus Paracasei Is Associated with Increased Levels of Angiopoietin-Like 4 Protein (ANGPTL4)	2415
13	[Lactobacillus paracasei] Effect of LactobacillusparacaseiST11 on a nasal provocation test with grass pollen in allergic rhinitis	2359
12	[Lactobacillus paracasei] Antimicrobial and antiadhesive properties of a biosurfactant isolated from Lactobacillus paracasei ssp.paracasei A20	2441
11	[Lactobacillus Plantarum] Cholesterol-lowering effects of a putative probiotic strain Lactobacillus plantarum EM isolated from kimchi	2459
10	[Bacillus] Anti-inﬂuenza Activity of a Bacillus subtilis Probiotic Strain	2119
9	[Bacillus] Aflatoxin B1 degradation by Bacillus subtilis UTBSP1 isolated from pistachio nuts of Iran	2272
8	[Lactobacillus Plantarum] Identification of Lactobacillus plantarum genes modulating the cytokine response of human peripheral blood mononuclear cells	2349
7	[Lactobacillus casei] Immunomodulatory effects of a probiotic drink containing Lactobacillus casei Shirota in healthy older volunteers	3239
6	[Bacillus]Microbial flora, probiotics, Bacillus subtilis and the search for a long and healthy human longevity	2125
5	[Lactobacillus casei] Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study	2340
4	[Saccharomyces cerevisiae] A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome.	2297
3	[Saccharomyces cerevisiae] Oral treatment with Saccharomyces cerevisiae strain UFMG 905 modulates immune responses and interferes with signal pathways involved in the activation of inflammation in ...	2112
2	[Lactobacillus casei] Effects of Lactobacillus casei supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double-blind clinical trial	2077
1	[Saccharomyces cerevisiae] Saccharomyces cerevisiae Modulates Immune Gene Expressions and Inhibits ETEC-Mediated ERK1/2 and p38 Signaling Pathways in Intestinal Epithelial Cell	2403

㈜마이크로바이옴 ㅣ 서울시 서대문구 연희로 77-12 영화빌딩2층

Tel :02-322-0302 l Fax : 02-322-0759

학술자료

Academic Material﻿

[Gut Microbiome] The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation

Academic Material